Cetuximab and panitumumab have been approved for the treatment of metastatic colorectal cancer when used alone or in combination with irinotecan. Although EGFR is expressed in most metastatic colorectal tumors, only a subset of patients derive clinical benefit from treatment with EGFR inhibitors. The experimental and clinical evidence supporting the use ofKRAStesting for selecting patients for treatment with anti-EGFR monoclonal antibodies is discussed.
- Nicola Normanno
- Sabine Tejpar
- Fortunato Ciardiello
